Jade Biosciences (JBIO) Amortizatization of Intangibles (2022 - 2026)
Jade Biosciences (JBIO) posted Amortizatization of Intangibles of $493000.0 for Q1 2026, down 19.18% on a QoQ basis from $610000.0 in Q4 2025, and up 319.11% year-over-year from $117629.9 in Q1 2025.
Jade Biosciences (JBIO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Jade Biosciences' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $493000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles rose 319.11% year-over-year to $493000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $542000.0 (up 131.62% YoY) and the FY2025 annual result came in at $784000.0, up 134.88% from the prior year.
- Amortizatization of Intangibles was $493000.0 for Q1 2026 at Jade Biosciences, down from $610000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $610000.0 in Q4 2025 and bottomed at -$939000.0 in Q4 2023.
- A 5-year average of -$355800.0 and a median of -$461000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles plunged 2413.79% — and 2026, when it surged 319.11%.
- Jade Biosciences' Amortizatization of Intangibles stood at -$586000.0 in 2022, then tumbled by 60.24% to -$939000.0 in 2023, then jumped by 64.22% to -$336000.0 in 2024, then soared by 281.55% to $610000.0 in 2025, then fell by 19.18% to $493000.0 in 2026.
- Business Quant data shows JBIO's Amortizatization of Intangibles at $493000.0 in Q1 2026, $610000.0 in Q4 2025, and -$225000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Jade Biosciences | 1.18 Bn | 866.20 Mn | - | 493,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 493,000.00 |
| Mar 31, 2026 | 493,000.00 |
| Dec 31, 2025 | 610,000.00 |
| Dec 31, 2025 | 610,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Dec 31, 2024 | -336,000.00 |
| Dec 31, 2024 | -336,000.00 |
| Sep 30, 2024 | -461,000.00 |
| Sep 30, 2024 | -461,000.00 |
| Jun 30, 2024 | -692,000.00 |
| Jun 30, 2024 | -692,000.00 |
| Mar 31, 2024 | -759,000.00 |
| Mar 31, 2024 | -759,000.00 |
| Dec 31, 2023 | -939,000.00 |
| Dec 31, 2023 | -939,000.00 |
| Sep 30, 2023 | -808,000.00 |
| Sep 30, 2023 | -808,000.00 |
| Jun 30, 2023 | -639,000.00 |
| Jun 30, 2023 | -639,000.00 |